Data

A feasibility study of lorazepam for anxiety in palliative care (LORAZEPAM Study)

Health Data Australia Contributor Records
HeSANDA, MACH ; Atkin, Dr Nicola ; Le, Professor Brian ; Philip, Professor Jennifer ; HeSANDA MACH Node
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.26188/22880612&rft.title=A feasibility study of lorazepam for anxiety in palliative care (LORAZEPAM Study)&rft.identifier=http://doi.org/10.26188/22880612&rft.publisher=The University of Melbourne&rft.description=Demographic data for 15 adult patients with advanced cancer or advanced life-limiting disease and persistent or recurrent anxiety causing clinically significant distress or functional impairment at time of enrolment. 11 patients randomised to regular lorazepam treatment arm, 4 randomised to placebo, and treated for up to 12 weeks. Data collected at baseline, week 1,2,4,8,12 and follow-up at week 16 unless early discontinuation. Data includes anxiety measures (HADS-A, PROMIS 7a short form, PGIC), functional status (AKPS), other symptoms (ESAS), health-related quality of life (EQ 5D 5L), sleepiness (ESS), other adverse events and feasibility outcome data (recruitment, retention, completion of assessments, survival, acceptability, burden).&rft.creator=HeSANDA, MACH &rft.creator=Atkin, Dr Nicola &rft.creator=Le, Professor Brian &rft.creator=Philip, Professor Jennifer &rft.creator=HeSANDA MACH Node &rft.date=2024&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12620001143910&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12620001143910&rft.coverage=Victoria, Australia&rft_rights=Restrictive Licence https://library.unimelb.edu.au/restricted-licence-template&rft_subject=Psychiatry (incl. psychotherapy)&rft_subject=Palliative care&rft.type=dataset&rft.language=English Access the data
Cite Saved to MyRDA Save to MyRDA

Licence & Rights:

view details

Access:

Other

Full description

Demographic data for 15 adult patients with advanced cancer or advanced life-limiting disease and persistent or recurrent anxiety causing clinically significant distress or functional impairment at time of enrolment. 11 patients randomised to regular lorazepam treatment arm, 4 randomised to placebo, and treated for up to 12 weeks. Data collected at baseline, week 1,2,4,8,12 and follow-up at week 16 unless early discontinuation. Data includes anxiety measures (HADS-A, PROMIS 7a short form, PGIC), functional status (AKPS), other symptoms (ESAS), health-related quality of life (EQ 5D 5L), sleepiness (ESS), other adverse events and feasibility outcome data (recruitment, retention, completion of assessments, survival, acceptability, burden).

Notes

HeSANDA 1.0.0

Created: 2024-08-01

Updated: 2024-08-01

Collected:

Data time period: 2021 to , 2022 to ,

This dataset is part of a larger collection

Click to explore relationships graph
Help

Related Publications

Related Data

Spatial Coverage And Location

text: Victoria, Australia

Subjects
Palliative care | Psychiatry (incl. psychotherapy) |

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Identifiers